Inflammatory signaling compromises cell responses to interferon alpha

Oncogene

Volumn 31, Issue 2, 2012, Pages 161-172

  Huangfu, W C ^a   Qian, J ^a   Liu, C ^b   Liu, J ^a   Lokshin, A E ^c   Baker, D P ^d   Rui, H ^b   Fuchs, S Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d BIOGEN   (United States)

Author keywords

cancer; inflammation; interferon; melanoma; receptor; ubiquitin

Indexed keywords

ALPHA INTERFERON RECEPTOR; ALPHA2 INTERFERON; BETA INTERFERON; INTERFERON RECEPTOR; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE P38; VX 702;

ANIMAL CELL; ARTICLE; CATALYSIS; CELL GROWTH; CELL VIABILITY; EMBRYO; ENZYME ACTIVATION; HUMAN; HUMAN CELL; INFLAMMATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; CELL LINE, TUMOR; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERFERON-ALPHA; MELANOMA; MICE; MICE, SCID; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 84855769864     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.221     Document Type: Article

References (55)

1. Aaronson DS, Horvath CM. (2002). A road map for those who don't know JAK-STAT. Science 296: 1653-1655. (Pubitemid 34579157)
2. Alonso-Curbelo D, Soengas MS. (2010). Self-killing of melanoma cells by cytosolic delivery of dsRNA: wiring innate immunity for a coordinated mobilization of endosomes, autophagosomes and the apoptotic machinery in tumor cells. Autophagy 6: 148-150.
3. Ascierto PA, Kirkwood JM. (2008). Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 6: 62.
4. Balkwill F, Mantovani A. (2010). Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 87: 401-406.
5. Bennicelli JL, Elias J, Kern J, Guerry Dt. (1989). Production of interleukin 1 activity by cultured human melanoma cells. Cancer Res 49: 930-935. (Pubitemid 19064349)
6. Bhattacharya S, HuangFu WC, Liu J, Veeranki S, Baker DP, Koumenis C et al. (2010). Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor. J Biol Chem 285: 2318-2325.
7. Bracarda S, Eggermont AM, Samuelsson J. (2010). Redefining the role of interferon in the treatment of malignant diseases. Eur J Cancer 46: 284-297.
8. Bregman H, Carroll PJ, Meggers E. (2006). Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. J Am Chem Soc 128: 877-884. (Pubitemid 43153038)
9. Coccia EM, Uze G, Pellegrini S. (2006). Negative regulation of type I interferon signaling: facts and mechanisms. Cell Mol Biol (Noisy-legrand) 52: 77-87. (Pubitemid 43925164)
10. Fecher LA, Flaherty KT. (2009). Where are we with adjuvant therapy of stage III and IV melanoma in 2009? J Natl Compr Canc Netw 7: 295-304.
11. Germano G, Allavena P, Mantovani A. (2008). Cytokines as a key component of cancer-related inflammation. Cytokine 43: 374-379.
12. Goldman LA, Zafari M, Cutrone EC, Dang A, Brickelmeier M, Runkel L et al. (1999). Characterization of antihuman IFNAR-1 monoclonal antibodies: epitope localization and functional analysis. J Interferon Cytokine Res 19: 15-26. (Pubitemid 29070228)
13. Grivennikov SI, Greten FR, Karin M. (2010). Immunity, inflammation, and cancer. Cell 140: 883-899.
14. Gu Y, Zeleniuch-Jacquotte A, Linkov F, Koenig KL, Liu M, Velikokhatnaya L et al. (2009). Reproducibility of serum cytokines and growth factors. Cytokine 45: 44-49.
15. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
16. Huangfu WC, Qian J, Liu C, Rui H, Fuchs SY. (2010). Melanoma cellsecreted soluble factor that stimulates ubiquitination and degradation of the interferon alpha receptor and attenuates its signaling. Pigment Cell Melanoma Res 23: 838-840.
17. Hui L, Bakiri L, Stepniak E, Wagner EF. (2007). p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle 6: 2429-2433. (Pubitemid 350058657)
18. Jinlian L, Yingbin Z, Chunbo W. (2007). p38 MAPK in regulating cellular responses to ultraviolet radiation. J Biomed Sci 14: 303-312.
19. Kaehler KC, Sondak VK, Schadendorf D, Hauschild A. (2010). Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. Eur J Cancer 46: 41-46.
20. Kock A, Schwarz T, Urbanski A, Peng Z, Vetterlein M, Micksche M et al. (1989). Expression and release of interleukin-1 by different human melanoma cell lines. J Natl Cancer Inst 81: 36-42. (Pubitemid 19020935)
21. Kumar KG, Barriere H, Carbone CJ, Liu J, Swaminathan G, Xu P et al. (2007a). Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis. J Cell Biol 179: 935-950. (Pubitemid 350223490)
22. Kumar KG, Krolewski JJ, Fuchs SY. (2004). Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J Biol Chem 279: 46614-46620. (Pubitemid 39518306)
23. Kumar KG, Liu J, Li Y, Yu D, Thomas-Tikhonenko A, Herlyn M et al. (2007b). Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biol Ther 6: 1437-1441. (Pubitemid 351590355)
24. Kumar KG, Tang W, Ravindranath AK, Clark WA, Croze E, Fuchs SY. (2003). SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J 22: 5480-5490. (Pubitemid 37279957)
25. Leiter U, Garbe C. (2008). Epidemiology of melanoma and nonmelanoma skin cancer-the role of sunlight. Adv Exp Med Biol 624: 89-103.
26. Li Y, Clevenger CV, Minkovsky N, Kumar KG, Raghunath PN, Tomaszewski JE et al. (2006). Stabilization of prolactin receptor in breast cancer cells. Oncogene 25: 1896-1902.
27. Lin WW, Karin M. (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183. (Pubitemid 46718402)
28. Linkov F, Ferris RL, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Gooding W et al. (2008). Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. Proteomics Clin Appl 2: 1575-1585.
29. Liu J, Carvalho LP, Bhattacharya S, Carbone CJ, Kumar KG, Leu NA et al. (2009). Mammalian casein kinase 1alpha and its leishmanial ortholog regulate stability of IFNAR1 and type I interferon signaling. Mol Cell Biol 29: 6401-6412.
30. Liu J, Plotnikov A, Banerjee A, Suresh Kumar KG, Ragimbeau J, Marijanovic Z et al. (2008). Ligand-independent pathway that controls stability of interferon alpha receptor. Biochem Biophys Res Commun 367: 388-393.
31. Liu J, Suresh Kumar KG, Yu D, Molton SA, McMahon M, HerlynM et al. (2007). Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene 26: 1954-1958. (Pubitemid 46474640)
32. Mantovani A, Allavena P, Sica A, Balkwill F. (2008). Cancer-related inflammation. Nature 454: 436-444.
33. Marijanovic Z, Ragimbeau J, Kumar KG, Fuchs SY, Pellegrini S. (2006). TYK2 activity promotes ligand-induced IFNAR1 proteolysis. Biochem J 397: 31-38. (Pubitemid 44032833)
34. Megason SG, McMahon AP. (2002). A mitogen gradient of dorsal midline Wnts organizes growth in the CNS. Development 129: 2087-2098. (Pubitemid 34874223)
35. Melnikova VO, Bar-Eli M. (2009). Inflammation and melanoma metastasis. Pigment Cell Melanoma Res 22: 257-267.
36. Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI. (2008). Activated stat-3 in melanoma. Cancer Control 15: 196-201.
37. Mocellin S, Pasquali S, Rossi CR, Nitti D. (2010). Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102: 493-501.
38. Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S et al. (1999). Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer 84: 160-168. (Pubitemid 29133828)
39. Nazarian RM, Prieto VG, Elder DE, Duncan LM. (2010). Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol 37(Suppl 1): 41-47.
40. Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA et al. (2010). Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem 285: 6477-6488.
41. Oxholm A, Oxholm P, Staberg B, Bendtzen K. (1988). Immunohistological detection of interleukin I-like molecules and tumour necrosis factor in human epidermis before and after UVBirradiation in vivo. Br J Dermatol 118: 369-376.
42. Platanias LC. (2005). Mechanisms of type-I-and type-II-interferonmediated signalling. Nat Rev Immunol 5: 375-386.
43. Rigual NR, Popat SR, Jayaprakash V, Jaggernauth W, Wong M. (2008). Cutaneous head and neck melanoma: the old and the new. Expert Rev Anticancer Ther 8: 403-412. (Pubitemid 351836288)
44. Roux PP, Blenis J. (2004). ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320-344. (Pubitemid 38756868)
45. Sander B, Boeryd B. (1996). Tumor necrosis factor-alpha expression in human primary malignant malanoma and it relationship to tumor infiltration by CD3+ cells. Int J Cancer 66: 42-47. (Pubitemid 26120898)
46. Smalley KS, Nathanson KL, Flaherty KT. (2009). Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 69: 3241-3244.
47. Soengas MS, Lowe SW. (2003). Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151. (Pubitemid 36713766)
48. Spiegelman VS, Tang W, Katoh M, Slaga TJ, Fuchs SY. (2002). Inhibition of HOS expression and activities by Wnt pathway. Oncogene 21: 856-860. (Pubitemid 34146298)
49. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J et al. (2000). Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer 85: 182-188. (Pubitemid 30023065)
50. Uze G, Schreiber G, Piehler J, Pellegrini S. (2007). The receptor of the type I interferon family. Curr Top Microbiol Immunol 316: 71-95.
51. Weber A, Wasiliew P, Kracht M. (2010). Interleukin-1 (IL-1) pathway. Sci Signal 3: cm1.
52. Yao K, Balch G, Winchester DJ. (2009). Multidisciplinary treatment of primary melanoma. Surg Clin North Am 89: 267-281, xi.
53. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT et al. (2007). Multiplex analysis of serum cytokines in melanoma patients treated with interferonalpha2b. Clin Cancer Res 13: 2422-2428. (Pubitemid 46698593)
54. Zheng H, Qian J, Varghese B, Baker DP, Fuchs S. (2011). Ligandstimulated downregulation of the alpha interferon receptor: role of protein kinase D2. Mol Cell Biol 31: 710-720.
55. Zwang Y, Yarden Y. (2006). p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. EMBO J 25: 4195-4206. (Pubitemid 44435217)